The relevance of nonmyeloablative transplants in developing countries: lessons from the UK experience.
Chakrabarti
S
S
Heartlands Hospital, Birmingham, London, United Kingdom. suparno@doctors.org.uk
Mackinnon
S
S
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000379:methods* / Q000401:mortality; D015331:Cohort Studies; D003431:Cross-Cultural Comparison; D003906:Developing Countries; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000517:prevention & control; D006650:Histocompatibility Testing; D006801:Humans; D033581:Stem Cell Transplantation / Q000379:methods* / Q000401:mortality; D015996:Survival Rate; D018183:Transplantation Chimera; D019172:Transplantation Conditioning / Q000379:methods*; D006113:United Kingdom; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab; D014740:Vidarabine; C024352:fludarabine